Gadowski G R, Pilcher D B, Ricci M A
Department of Surgery, University of Vermont College of Medicine, Burlington.
J Vasc Surg. 1994 Apr;19(4):727-31. doi: 10.1016/s0741-5214(94)70048-6.
The purpose of this study was to investigate the hypothesis that abdominal aortic aneurysm (AAA) expansion may be slowed by beta-adrenergic antagonists.
One hundred twenty-one patients with infrarenal AAA were monitored with serial aortic ultrasound examinations. Eighty-three patients received no beta-blockers (group I), and 38 patients received beta-blockers (group II). Values are expressed as mean +/- SD.
The mean follow-up was 43 +/- 29 months with 5.5 +/- 3.4 ultrasound examinations per patient. The expansion rate among all AAA was 0.38 +/- 0.44 cm/yr. Large aneurysms (> or = 5 cm) expanded significantly faster than small aneurysms (p = 0.02) in patients not treated with beta-blockers. Among patients with large AAA, those receiving beta-blockers had a significantly reduced mean expansion rate; 0.36 +/- 0.20 versus 0.68 +/- 0.64 cm/yr, (p < 0.05). Although rupture rates were lower in group I (5%) versus group II (13%), this difference was not statistically significant. Thirty-four patients in a poor-risk category with AAA were monitored greater than 5 cm in diameter. Ten of these AAA ruptured. The mean expansion rate was significantly greater in those patients with ruptured AAA versus those patients with AAA that did not rupture; 0.82 +/- 0.74 versus 0.42 +/- 0.41 cm/yr (p = 0.04).
In patients not undergoing beta-blocker therapy, large AAA expand at a significantly greater rate than smaller AAA. Large aneurysms that rupture show more rapid expansion than those AAA that do not rupture. We have demonstrated a significantly reduced rate of expansion of large AAA in patients receiving beta-blockade.
本研究旨在探讨β-肾上腺素能拮抗剂可能减缓腹主动脉瘤(AAA)扩张这一假说。
对121例肾下腹主动脉瘤患者进行系列主动脉超声检查监测。83例患者未接受β受体阻滞剂治疗(I组),38例患者接受β受体阻滞剂治疗(II组)。数值以均值±标准差表示。
平均随访时间为43±29个月,每位患者平均接受5.5±3.4次超声检查。所有腹主动脉瘤的扩张率为0.38±0.44 cm/年。在未接受β受体阻滞剂治疗的患者中,大动脉瘤(≥5 cm)的扩张速度明显快于小动脉瘤(p = 0.02)。在大腹主动脉瘤患者中,接受β受体阻滞剂治疗的患者平均扩张率显著降低;分别为0.36±0.20 cm/年和0.68±0.64 cm/年,(p < 0.05)。虽然I组的破裂率(5%)低于II组(13%),但这一差异无统计学意义。对34例直径大于5 cm的高危腹主动脉瘤患者进行了监测。其中10例腹主动脉瘤破裂。破裂的腹主动脉瘤患者的平均扩张率显著高于未破裂的腹主动脉瘤患者;分别为0.82±0.74 cm/年和0.42±0.41 cm/年(p = 0.04)。
在未接受β受体阻滞剂治疗的患者中,大腹主动脉瘤的扩张速度明显快于小腹主动脉瘤。破裂的大动脉瘤比未破裂的腹主动脉瘤扩张更快。我们已证明接受β受体阻滞剂治疗的患者大腹主动脉瘤的扩张率显著降低。